Victory Capital Management
EIDX

Victory Capital Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Victory Capital Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,732
Closed -$754K – 2802
2020
Q4 		$754K Sell
5,732
-47,377
-89% -$4.19M ﹤0.01% 1895
2020
Q3 		$2.68M Sell
53,109
-6,405
-11% -$288K ﹤0.01% 1362
2020
Q2 		$2.84M Sell
59,514
-279,940
-82% -$13M ﹤0.01% 1324
2020
Q1 		$16.6M Buy
339,454
+164,652
+94% +$8.39M 0.01% 942
2019
Q4 		$10M Sell
174,802
-94,101
-35% -$4.66M 0.01% 1012
2019
Q3 		$9.67M Buy
268,903
+158,173
+143% +$6.18M 0.01% 994
2019
Q2 		$3.44M Sell
110,730
-72,440
-40% -$1.96M 0.01% 1001
2019
Q1 		$4.29M Sell
183,170
-22,850
-11% -$367K 0.01% 881
2018
Q4 		$2.83M Buy
+206,020
New +$2.6M 0.01% 950

Victory Capital Management's EIDX Position: Q1 2021 in Review

Victory Capital Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 5,732 shares — an estimated $754K sold.

Victory Capital Management first reported a position in EIDX in Q4 2018 and held it in 9 quarters. The position peaked at $16.6M in Q1 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Victory Capital Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Victory Capital Management sold 5,732 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $754K.
  • Victory Capital Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2018 and held it in 9 quarters.
  • Victory Capital Management's Eidos Therapeutics, Inc. Common Stock position peaked at $16.6M in Q1 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Victory Capital Management's 13F filing for Q1 2021, filed 4 May 2021.